ClinicalTrials.Veeva

Menu

High Protein Breakfast on Appetite, Postprandial Glycemia and Weight Loss in T2D (HPB)

H

Hospital de Clinicas Caracas

Status

Unknown

Conditions

Type 2 Diabetes

Treatments

Other: Arm 2 No Whey Breakfast
Other: Arm 1 Whey Breakfast
Other: Arm 3 Low Protein Breakfast

Study type

Interventional

Funder types

Other

Identifiers

NCT01623648
HCCCBI 017-2007-104

Details and patient eligibility

About

The investigators hypothesis is that eating whey protein in the breakfast versus other proteins will results in higher satiety, reduced overall postprandial glycemia and more weight loss in obese diabetic individuals

Full description

Recently we have shown that compared to low carbohydrate diet, an isocaloric diet with addition of high calorie and protein breakfast promoted sustained weight loss and prevented weight regain by reducing diet-induced compensatory changes in hunger, cravings and ghrelin suppression.

However the effect of isocaloric and isoproteic breakfast with different source of proteins, (whey vs other proteins or vs low protein in breakfast) on weight loss, appetite and on glycemic fluctuations after breakfast lunch and dinner was not explored in obese diabetic individuals.

To search whether compared to proteins like tuna, eggs and soy, the intake of whey protein in the breakfast will lead to reduced hunger and overall postprandial glycemia and will enhance weight loss in obese diabetic individuals

Enrollment

58 estimated patients

Sex

All

Ages

30 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Subjects ≥30 and ≤70 years of age
  2. BMI: 26 to 34 kg/m2)
  3. Diabetes criteria
  4. HbA1C: 7-9 % or
  5. Habitually eat breakfast
  6. Only naïve or treated with metformin.
  7. Those with anti-hypertensive and lipid-lowering medication will be included.
  8. . Not dieting and no change in body weight >10 lb = 4.5 kg within the last 6 months

10.Those who provide signed informed consent 11.Stable physical activity pattern during the three months immediately preceding study initiation.

  1. Normal liver, kidney and thyroid function. 13. Negative urinary microalbumin test (urMA) and estimated glomerular filtration rate (GFR) > 60 mL/min/1.73 m2.

Exclusion criteria

  1. Type 1 Diabetes

  2. Clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric, infectious, malignant disease

  3. Anemia (Hg > 10 g/dL)

  4. Serum creatinine level < 1.5 mg/dl

  5. Pulmonary disease, psychiatric, immunological, neoplastic diseases or severe diabetic complications, such as cardiovascular disease, cerebrovascular disease, proliferative diabetic retinopathy, gastroparesis or underwent bariatric surgery.

  6. Abnormal liver function tests defined as an increase by a factor of at least 2 above the upper normal limit of alanine aminotransferase and/or aspartate

  7. Infectious disease

  8. Malignancy

  9. Pregnant women or lactating

  10. Known hypersensitivity to milk components

  11. Participating in dietary program or using of weight-loss medications 11. Documented or suspected history (within one year) of illicit drug abuse or alcoholism.

  12. Use of psychotropic, anorectic or steroid medication during the month immediately prior to study onset

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

58 participants in 3 patient groups, including a placebo group

Arm 1 Whey Breakfast
Experimental group
Description:
The arm 1 will be assigned to eating Whey protein in the breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 42 g protein namely from whey at breakfast
Treatment:
Other: Arm 1 Whey Breakfast
Arm 2: No Whey Breakfast
Active Comparator group
Description:
The arm 2 will be assigned to intake other proteins (No Whey) in the breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 42 g protein from other sources at breakfast
Treatment:
Other: Arm 2 No Whey Breakfast
Arm 3: Low Protein Breakfast
Placebo Comparator group
Description:
The arm 3 will be assigned to intake low protein and high carbohydrate breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 22 g protein from other sources at breakfast
Treatment:
Other: Arm 3 Low Protein Breakfast

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems